|
1
|
Bartlett JG, Chang TW, Gurwith M, et al:
Antibiotic-associated pseudomembranous colitis due to
toxin-producing clostridia. N Engl J Med. 298:531–534. 1978.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McFarland LV, Surawicz CM and Stamm WE:
Risk factors for Clostridium difficile carriage and C.
difficile-associated diarrhea in a cohort of hospitalized
patients. J Infect Dis. 162:678–684. 1990.
|
|
3
|
Freeman J, Bauer MP, Baines SD, et al: The
changing epidemiology of Clostridium difficile infections.
Clin Microbiol Rev. 23:529–549. 2010. View Article : Google Scholar
|
|
4
|
Arroyo LG1, Kruth SA, Willey BM, Staempfli
HR, Low DE and Weese JS: PCR ribotyping of Clostridium difficile
isolates originating from human and animal sources. J Med
Microbiol. 54:163–166. 2005.PubMed/NCBI
|
|
5
|
Hatheway CL: Toxigenic clostridia.
Clin Microbiol Rev. 3:66–98. 1990.
|
|
6
|
Spigaglia P and Mastrantonio P:
Comparative analysis of Clostridium difficile clinical
isolates belonging to different genetic lineages and time periods.
J Med Microbiol. 53:1129–1136. 2004.
|
|
7
|
Martirosian G: Recovery of Clostridium
difficile from hospital environments. J Clin Microbiol.
44:1202–1203. 2006.
|
|
8
|
Samie A, Obi CL, Franasiak J, et al: PCR
detection of Clostridium difficile triose phosphate
isomerase (tpi), toxin A (tcdA), toxin B (tcdB), binary toxin
(cdtA, cdtB), and tcdC genes in Vhembe District, South Africa. Am J
Trop Med Hyg. 78:577–585. 2008.
|
|
9
|
Frias-Lopez J, Shi Y, Tyson GW, et al:
Microbial community gene expression in ocean surface waters. Proc
Natl Acad Sci USA. 105:3805–3810. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu S, Zhang L, Zhang C, et al: Comparison
of polymerase chain reaction ribotyping, toxinotyping and
nutritional aspects of toxin production of Clostridium
difficile strains. Biomed Rep. 2:477–480. 2014.PubMed/NCBI
|
|
11
|
Bélanger SD, Boissinot M, Clairoux N, et
al: Rapid detection of Clostridium difficile in feces by
real-time PCR. J Clin Microbiol. 41:730–734. 2003.
|
|
12
|
John R and Brazier JS: Antimicrobial
susceptibility of polymerase chain reaction ribotypes of
Clostridium difficile commonly isolated from symptomatic
hospital patients in the UK. J Hosp Infect. 61:11–14. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Clinical and Laboratory Standards
Institute (CLSI). Methods for antimicrobial susceptibility testing
of anaerobic bacteria, approved standard M11-A7. 7th edition. CLSI;
Wayne, PA: pp. 309–315. 2007
|
|
14
|
Persson S, Jensen JN and Olsen KE:
Multiplex PCR method for detection of Clostridium difficile
tcdA, tcdB, cdtA, and cdtB and internal in-frame deletion of tcdC.
J Clin Microbiol. 49:4299–4300. 2011.PubMed/NCBI
|
|
15
|
Jayaratne PA, Monkman L, Broukhanski G, et
al: Real-time polymerase chain reaction method for detection of
toxigenic Clostridium difficile from stools and presumptive
identification of NAP1 clone. Diagn Microbiol Infect Dis.
75:121–123. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Du P, Cao B, Wang J, et al: Sequence
variation in tcdA and tcdB of Clostridium difficile: ST37 with
truncated tcdA is a potential epidemic strain in China. J Clin
Microbiol. June.23–2014.(Epub ahead of print).
|
|
17
|
Geric B, Rupnik M, Gerding DN, et al:
Distribution of Clostridium difficile variant toxinotypes
and strains with binary toxin genes among clinical isolates in an
American hospital. J Med Microbiol. 53:887–894. 2004.
|
|
18
|
Kim H, Riley TV, Kim M, et al: Increasing
prevalence of toxin A-negative, toxin B-positive isolates of
Clostridium difficile in Korea: impact on laboratory
diagnosis. J Clin Microbiol. 46:1116–1117. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Saujet L, Monot M, Dupuy B, et al: The key
sigma factor of transition phase, SigH, controls sporulation,
metabolism, and virulence factor expression in Clostridium
difficile. J Bacteriol. 193:3186–3196. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gerding DN, Johnson S, Rupnik M and
Aktories K: Clostridium difficile binary toxin CDT:
mechanism, epidemiology, and potential clinical importance. Gut
Microbes. 5:15–27. 2014. View Article : Google Scholar
|
|
21
|
Goldenberg SD and French GL: Lack of
association of tcdC type and binary toxin status with
disease severity and outcome in toxigenic Clostridium
difficile. J Infect. 62:355–362. 2011.
|
|
22
|
Antunes A and Dupuy B: Molecular methods
to study transcriptional regulation of Clostridium difficile
toxin genes. Methods Mol Biol. 646:93–115. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Spigaglia P, Barbanti F, Dionisi AM and
Mastrantonio P: Clostridium difficile isolates resistant to
fluoroquinolones in Italy: emergence of PCR ribotype 018. J Clin
Microbiol. 48:2892–2896. 2010. View Article : Google Scholar
|
|
24
|
Gerding DN, Muto CA and Owens RC Jr:
Treatment of Clostridium difficile infection. Clin Infect
Dis. 46(Suppl 1): S32–S42. 2008.
|
|
25
|
Settle CD, Wilcox MH, Fawley WN, et al:
Prospective study of the risk of Clostridium difficile
diarrhoea in elderly patients following treatment with cefotaxime
or piperacillin-tazobactam. Aliment Pharmacol Ther. 12:1217–1223.
1998.PubMed/NCBI
|
|
26
|
Cheng SH, Chu FY, Lo SH and Lu JJ:
Antimicrobial susceptibility of Clostridium difficile by E
test. J Microbiol Immunol Infect. 32:116–120. 1999.
|
|
27
|
Ednie LM, Jacobs MR and Appelbaum PC:
Activities of gatifloxacin compared to those of seven other agents
against anaerobic organisms. Antimicrob Agents Chemother.
42:2459–2462. 1998.PubMed/NCBI
|
|
28
|
Lin YC, Huang YT, Tsai PJ, et al:
Antimicrobial susceptibilities and molecular epidemiology of
clinical isolates of Clostridium difficile in Taiwan.
Antimicrob Agents Chemother. 55:1701–1705. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hecht DW, Galang MA, Sambol SP, et al: In
vitro activities of 15 antimicrobial agents against 110 toxigenic
Clostridium difficile clinical isolates collected from 1983
to 2004. Antimicrob Agents Chemother. 51:2716–2719. 2007.PubMed/NCBI
|
|
30
|
Larson KC, Belliveau PP and Spooner LM:
Tigecycline for the treatment of severe Clostridium
difficile infection. Ann Pharmacother. 45:1005–1010. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wilcox MH: Evidence for low risk of
Clostridium difficile infection associated with tigecycline.
Clin Microbiol Infect. 13:949–952. 2007.PubMed/NCBI
|
|
32
|
Baines SD, Saxton K, Freeman J, et al:
Tigecycline does not induce proliferation or cytotoxin production
by epidemic Clostridium difficile strains in a human gut
model. J Antimicrob Chemother. 58:1062–1065. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Herpers BL, Vlaminckx B, Burkhardt O, et
al: Intravenous tigecycline as adjunctive or alternative therapy
for severe refractory Clostridium difficile infection. Clin
Infect Dis. 48:1732–1735. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Critchley IA, Green LS, Young CL, et al:
Spectrum of activity and mode of action of REP3123, a new
antibiotic to treat Clostridium difficile infections. J
Antimicrob Chemother. 63:954–963. 2009. View Article : Google Scholar : PubMed/NCBI
|
